Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatric NPs Can Do in Michigan

If you’re a psychiatrist or PMHNP and you’ve noticed the explosion of GLP-1 medications like Wegovy and Ozempic, you might be wondering: Can I prescribe these? Should I? And does it even make sense for my practice?

The short answer: Yes, you can prescribe weight-loss medications in most states — but the rules, scope considerations, and economics vary dramatically depending on your credentials, location, and practice model.

This guide breaks down everything you need to know: who can prescribe what, state-by-state regulations, telehealth restrictions, reimbursement realities, and whether adding weight management to your psychiatric practice is the right move.

The Psychiatrist’s Case for Weight Management

Let’s start with the why. Why would a psychiatrist prescribe weight-loss medications?

Because metabolic and mental health are inseparable. Many of your patients struggle with medication-induced weight gain from antipsychotics or mood stabilizers. Others have obesity that worsens their depression, anxiety, or self-esteem. The rise of GLP-1 medications (semaglutide, tirzepatide, liraglutide) has created an opportunity to address both issues simultaneously.

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, frames it this way: ‘If we truly understand that metabolic and psychiatric systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ You already monitor glucose levels, lipids, and metabolic panels for patients on psychiatric meds — prescribing a GLP-1 to address weight gain isn’t outside your scope if you have the competency.

The safety concern: Early reports suggested GLP-1s might increase suicidal ideation. Current evidence disagrees. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. FDA and EMA reviews confirmed no causal link. In fact, some trials showed lower rates of depressive symptoms in GLP-1 groups, likely due to improved quality of life and reduced inflammation.

The scope question: ‘Is this within my lane?’ Yes — if you gain the proper training. Many psychiatrists are obtaining American Board of Obesity Medicine (ABOM) certification to formalize their competency. This requires ~60 hours of obesity-focused CME and passing an exam. It’s not required legally, but it strengthens your position and ensures you’re treating the whole patient, not just dabbling.

The key: don’t expand scope to ‘grab more patients’ — do it to offer integrated care to the patients you already see who will benefit.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Who Can Prescribe Weight-Loss Medications? Psychiatrists vs. PMHNPs

Psychiatrists (MD/DO): Full Authority, Few Restrictions

You have broad prescriptive authority in all 50 states. You can prescribe:

• GLP-1 agonists (Wegovy, Ozempic, Saxenda, Mounjaro) — non-controlled, FDA-approved for obesity or diabetes
• Phentermine (Schedule IV) — a common appetite suppressant, controlled substance
• Other weight-loss drugs like naltrexone-bupropion (Contrave), orlistat, etc.

No additional certification is legally required. Your DEA license and state medical license cover these medications. However, state medical boards do expect you to practice within the standard of care — meaning you should document appropriate indications (BMI ≥30 or ≥27 with comorbidities), obtain informed consent, and monitor patients regularly.

Some states have specific obesity treatment rules (more on that below in the state-by-state section). For example, Florida requires documented BMI criteria, written consent, and follow-ups every 3 months. New Jersey mandates a comprehensive workup including mental health screening. These apply to all prescribers, not just MDs, but as a psychiatrist you’re well-positioned to meet them.

Telehealth prescribing: You can prescribe weight-loss medications via telehealth in most states, provided you establish a valid doctor-patient relationship (typically a video visit). Federal DEA waivers currently allow prescribing controlled substances like phentermine remotely through December 31, 2025 — but state laws can override federal rules. More on that in the telehealth section.

PMHNPs: It Depends on Your State (and Experience)

Your ability to prescribe weight-loss medications independently depends entirely on your state’s scope-of-practice laws. Here’s the breakdown:

Full Practice Authority States (~24 states + D.C.)

In states with FPA, you can evaluate, diagnose, and prescribe medications — including weight-loss drugs — without physician oversight, once you meet experience requirements. Examples:

• New York: After 3,600 hours of practice (~2 years full-time), you can practice independently. You’ll still need to document competency, but no formal physician collaboration is required.
• Illinois: After 4,000 hours and 250 hours of continuing education, you can apply for Full Practice Authority. You can then prescribe GLP-1s and even controlled substances (with some Schedule II consulting requirements initially).
• California: AB 890 is phasing in independence. As of 2023, experienced NPs can work in group settings without physician protocols. By January 2026, ‘104’ NPs can open independent practices. However, California’s Corporate Practice of Medicine doctrine still requires physician involvement in clinic ownership/structure.

Practical caveat: Even in FPA states, some insurers or pharmacies push back on NP-written prescriptions for high-cost drugs like GLP-1s, especially if the NP isn’t the primary care provider. You may need to navigate prior authorizations that ask for ‘physician oversight’ even if not legally required.

Reduced/Restricted Practice States (~26 states)

You must have a collaborative agreement or supervision with a physician to prescribe. The level of oversight varies:

• Texas: Strict delegation state. You must have a Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. The PAA must specify what you can prescribe (including weight-loss meds), require monthly quality review meetings, and limit one physician to supervising up to 7 NPs/PAs. You cannot prescribe anything without this agreement.

• Florida: You must practice under a written protocol with a supervising physician. Florida’s ‘Autonomous APRN’ designation is limited to certain primary care specialties and excludes PMHNPs. Even autonomous NPs cannot prescribe controlled substances independently. Bottom line: as a psych NP in Florida, you need physician collaboration for all prescribing, including weight-loss medications.

• Pennsylvania: Collaborative practice required. Your written agreement must list the categories of drugs you can prescribe. Prescription pads must include both your name and your collaborating physician’s name. One physician can collaborate with up to four NPs.

Specialty scope concern: You’re trained as a psychiatric NP. Does prescribing weight-loss medications fall within your scope? Legally, scope is about competency, not just your specialty title. If you’re managing a patient’s antipsychotic-induced weight gain with a GLP-1, that’s arguably within psychiatric care. If you’re opening a standalone weight-loss clinic for the general public without additional training, state boards might scrutinize that.

Best practice: Pursue additional training (obesity management courses, certifications) and document that you’re treating weight as part of holistic psychiatric care. If your state requires collaboration, ensure your supervising physician is comfortable with — and explicitly authorizes — weight-loss prescribing in your agreement.

Telehealth Prescribing: Federal Waivers vs. State Red Lights

Telehealth has made weight-loss medication management scalable, but you need to navigate a patchwork of federal and state rules.

Federal Rules (Ryan Haight Act and DEA Waivers)

Pre-pandemic, the Ryan Haight Act required an in-person exam before prescribing any controlled substance (including phentermine). COVID-19 waivers suspended this. The DEA has extended telehealth flexibilities multiple times; as of late 2025, the Fourth Extension runs through December 31, 2025, allowing providers to prescribe controlled substances via telehealth without a prior in-person visit, provided they conduct an adequate evaluation (typically video).

Key point: This is a federal allowance. It does not override stricter state laws.

State Restrictions: Where Federal Permission Meets State Prohibition

About 8 states have telemedicine prescribing restrictions that go beyond federal rules, effectively banning or limiting remote controlled-substance prescribing. The two biggest concerns for weight-loss prescribers:

Florida: The ‘No Controlled Substances via Telehealth’ Rule

Florida law (F.S. 456.47) prohibits prescribing controlled substances via telehealth except for:

• Psychiatric treatment
• Inpatient/hospice care
• Acute pain or addiction treatment

Weight loss is not an exception. This means you cannot prescribe phentermine (Schedule IV) via telehealth to a Florida patient, even though federal DEA waivers allow it. If you do, you’re violating Florida law.

Workaround: You can prescribe non-controlled GLP-1s (Wegovy, Ozempic, etc.) via telehealth in Florida, as long as you meet the state’s obesity treatment standards (see state-by-state section below). Many Florida telehealth weight-loss programs avoid phentermine entirely and focus on GLP-1s.

Alabama: In-Person Exam Required for Controlled Substances

Alabama law mandates an initial in-person exam before prescribing any controlled substance, regardless of federal waivers. Telehealth-only practices cannot start patients on phentermine without arranging a local exam first.

Other States to Watch

• South Carolina, Idaho, New Jersey: Have various telemedicine restrictions that may require in-person exams or impose extra documentation for controlled substances.

In contrast, ~42 states align with federal telehealth flexibilities and have no extra state-level barriers. This includes New York, Pennsylvania, Illinois, California, and Texas (though Texas has other rules — see below).

Bottom line for telehealth prescribers:

• For GLP-1s and non-controlled weight-loss drugs, telehealth is broadly permissible across all states (assuming you meet standard-of-care requirements).
• For phentermine or other controlled substances, check both federal waivers and your patient’s state law. Florida and Alabama are non-starters for remote controlled prescribing.

State-by-State Requirements: What You Need to Know

Each state has its own rules for weight-loss prescribing, NP scope, and telehealth. Here’s what matters in the six highest-volume states:

California

• NP Scope: Transitioning to FPA via AB 890. Experienced NPs can practice independently in group settings (since 2023); full independent practice (including opening clinics) starts January 2026. However, Corporate Practice of Medicine rules still require physician involvement in clinic ownership.
• Prescribing: Psychiatrists have full authority. NPs can prescribe under physician protocols now; after FPA, they can prescribe non-controlled meds independently. Controlled substances (like phentermine) still require physician delegation until full FPA.
• Telehealth: No state restrictions on remote prescribing. Telehealth parity law in effect (insurers must reimburse telehealth at same rate as in-person).
• Obesity Rules: No specific state guidelines beyond standard medical practice.

Texas

• NP Scope: Strict delegation state. All NPs need a Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. One physician can supervise up to 7 NPs.
• Prescribing: Psychiatrists can prescribe weight-loss meds freely (except Schedule II stimulants are prohibited for weight loss by state law). NPs must have explicit authorization in their PAA for weight-loss drugs.
• Telehealth: Allowed for prescribing as long as standard of care is met. No state ban on controlled substances via telehealth (federal rules apply). Must check Texas PMP for controlled drugs.
• Obesity Rules: No specific state obesity treatment guidelines, but quality oversight required in PAAs (monthly MD-NP meetings, chart reviews).
• Note: Texas has strong Corporate Practice of Medicine enforcement — clinics must be physician-led or use MSO structures.

Florida

• NP Scope: Collaborative practice required (protocol with supervising physician). ‘Autonomous APRN’ status excludes PMHNPs and doesn’t allow independent controlled-substance prescribing. One physician can supervise up to 4 NPs via protocol.
• Prescribing: Strict rules. Patients must have BMI ≥30 (or ≥27 with comorbidity) documented. Informed written consent required. Follow-ups every 3 months mandatory. Must provide state’s ‘Weight-Loss Consumer Bill of Rights.’
• Telehealth: Cannot prescribe controlled substances (like phentermine) via telehealth unless treating a psychiatric disorder (gray area — risky to rely on this exception for weight loss). GLP-1s (non-controlled) are allowed via telehealth.
• Obesity Rules: Must conduct comprehensive exam (can delegate to APRN/PA). Must check PDMP before each controlled prescription.
• Clinic Requirements: Weight-loss clinics must register under Health Care Clinic Act and have a Florida-licensed MD as medical director.

Key Takeaway: Florida is highly regulated. Telehealth weight-loss programs in Florida typically avoid phentermine and focus on GLP-1s. Ensure physician collaboration and strict compliance with 3-month follow-up rules.

New York

• NP Scope: Reduced practice state. NPs need physician collaboration initially; after 3,600 hours, can practice independently (NP Modernization Act). No strict ratios.
• Prescribing: No state-specific obesity treatment rules. Must check NY PMP (I-STOP) before prescribing any Schedule II-IV controlled substance.
• Telehealth: No state restrictions. Telehealth payment parity law in effect since 2022 (commercial insurers must reimburse telehealth equally).
• Obesity Rules: Follow standard clinical guidelines (BMI criteria, informed consent, monitoring). Some insurers require documentation of lifestyle interventions.

Note: NY AG has scrutinized telehealth companies for substandard care. Document thorough evaluations.

Pennsylvania

• NP Scope: Collaborative practice required (no FPA yet). Written agreement with physician needed. Physician’s name must appear on prescriptions alongside NP’s. One physician can collaborate with up to 4 NPs.
• Prescribing: No state-specific obesity rules. NP collaboration agreements should specify authority to prescribe weight-loss drugs (including controlled substances if applicable).
• Telehealth: Allowed. No state ban on controlled-substance prescribing via telehealth. Telehealth parity for mental health services (Act 69); general telehealth reimbursement varies by insurer.
• Obesity Rules: None specific to state law; follow standard of care.

Illinois

• NP Scope: Partial FPA state. NPs can obtain Full Practice Authority after 4,000 hours and 250 hours CE. FPA NPs can prescribe independently, including controlled substances (with some Schedule II consulting requirements in first year).
• Prescribing: No state-specific obesity treatment guidelines. Must obtain separate Illinois Controlled Substance license to prescribe controlled drugs.
• Telehealth: Strong telehealth parity law (Telehealth Act). No state restrictions on remote prescribing. Must check Illinois PMP for controlled substances.
• Reimbursement: Illinois Medicaid reimburses APRNs at 100% of physician rates — a financial advantage for NPs.

Note: Illinois is NP-friendly. Experienced psych NPs with FPA can independently manage weight-loss patients, including prescribing GLP-1s and phentermine (with proper documentation).

Reimbursement: Can You Actually Get Paid?

Adding weight management to your practice only makes sense if you can get reimbursed (or patients will pay cash). Here’s the reality:

Insurance Coverage for GLP-1 Medications

The landscape is improving rapidly:

• Private Insurance: Many commercial plans now cover GLP-1s for obesity (Wegovy, Saxenda, Mounjaro) with prior authorization. Typical requirements: BMI ≥30 (or ≥27 with comorbidities), documentation of lifestyle interventions, and physician attestation. Some plans impose 30-day supply limits initially to monitor adherence.

• Medicare: Historically excluded weight-loss drugs. Major change in 2025: Medicare will begin covering anti-obesity medications (Wegovy, Mounjaro) starting in 2026 after price negotiations. This opens treatment to millions of seniors and significantly expands the market.

• Medicaid: Coverage varies by state. Some state Medicaid programs already cover at least one GLP-1 for obesity; more will likely expand coverage following Medicare’s lead.

Bottom line: More payers are covering weight-loss medications, meaning patients are more likely to engage (and you’re more likely to get paid through insurance rather than cash-only models).

Billing for Visits

For the consultation itself, you bill standard E/M codes (99202-99215 series) or psychiatric evaluation codes (90792, 90833). If you’re managing weight alongside a psychiatric condition, you can document both and bill based on total complexity.

Telehealth parity laws in California, New York, Illinois, and Pennsylvania ensure insurers reimburse telehealth visits at the same rate as in-person. Medicare also pays telehealth mental health visits at parity (and has permanently allowed tele-mental health to patients’ homes).

Reimbursement rates:

• Psychiatrists (MD/DO): Paid at 100% of physician fee schedule. Initial psychiatric evaluation with med management (90792) pays ~$200 via Medicare; routine 15-minute med checks (99213-99214) pay $75-$120.
• PMHNPs: Paid at 85% of physician fee schedule by Medicare (when billing under NP NPI). Some private insurers pay 85-100%. Illinois Medicaid pays NPs at 100% of physician rates — a rare parity win.

Key point: Medication management is financially sustainable, especially via telehealth where you can see higher volumes of shorter visits (15-minute check-ins to monitor weight, side effects, adjust dosage).

Prior Authorizations and Documentation

Expect to submit PAs for GLP-1s. Insurers want to see:

• BMI documentation
• Comorbidities (diabetes, hypertension, sleep apnea)
• Evidence of prior lifestyle modifications (diet, exercise programs)
• Treatment plan with follow-up schedule

Pro tip: Many telehealth platforms (like Klarity) handle PA paperwork for you or provide templates that auto-populate patient data, reducing your administrative burden.

The Economics of Adding Weight Management to Your Practice

Let’s talk real numbers. Should you add weight-loss prescribing to your psychiatric practice?

Traditional Marketing Costs: The $200-500+ Reality

If you try to build a weight-loss patient base through DIY marketing, here’s what you’re actually spending:

• SEO: Takes 6-12 months of consistent investment ($2,000-5,000/month for agency work) before generating meaningful patient flow. Most solo providers don’t have the expertise or patience.

• Google Ads: Mental health + weight-loss keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. Realistic cost per booked patient through PPC is $200-400+ (factoring in failed clicks, no-shows, and ad spend testing).

• Directory Listings (Psychology Today, Zocdoc): Monthly subscription fees + competition with hundreds of other providers on the same page. Zocdoc charges $35-100+ per booking, but total monthly cost (subscription + per-booking fees) adds up to hundreds.

• Total Cost Per New Patient: When you factor in agency fees, ad spend optimization, staff time handling leads, no-show rates from cold leads, and months of investment before results, acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+.

Reality check: Most solo providers don’t have $3,000-5,000/month to gamble on marketing with uncertain results.

The Klarity Model: Pay Only When You See Patients

Klarity Health uses a pay-per-appointment model similar to Zocdoc — but with key differences:

• No upfront marketing spend: Zero monthly subscriptions or retainer fees.
• Pre-qualified patients: Patients are already matched to your specialty (psychiatry + weight management if you offer it) and availability.
• No wasted ad spend: You’re not paying $30/click hoping someone books. You pay a standard listing fee only when a qualified patient books an appointment with you.
• Built-in telehealth infrastructure: No separate platform costs (EMR, video, prescribing tools included).
• Both insurance and cash-pay patient flow: Klarity handles insurance credentialing and billing, or you can see self-pay patients.
• You control your schedule: Only pay when you see patients. If you’re on vacation, no fees.

The math: Instead of spending $3,000-5,000/month on marketing hoping to land 10-15 patients (with no guarantees), you pay per completed appointment. Guaranteed ROI — you only pay when you deliver care.

For providers starting out or scaling: This removes the biggest barrier — patient acquisition risk. You’re not gambling on whether your Google Ads will convert or your SEO will rank. You’re getting patients who are ready to book.

DIY Marketing: When Does It Make Sense?

To be fair: DIY marketing can eventually be cost-effective if you have:

• The budget to invest $3,000-5,000/month for 6-12 months with no immediate return
• Expertise in SEO and PPC (or willingness to hire a $3,000+/month agency)
• Patience to wait 6-12 months for SEO to generate organic traffic
• Staff to handle and qualify inbound leads (and deal with no-shows from cold leads)

For most providers — especially those starting out, scaling, or juggling clinical work — a platform that handles patient acquisition is the smart choice.

FAQ: Weight-Loss Prescribing for Psychiatrists and PMHNPs

Can psychiatrists legally prescribe GLP-1 medications like Wegovy or Ozempic?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all 50 states for FDA-approved weight-loss medications, including GLP-1 agonists. You must practice within the standard of care (document appropriate indications, obtain informed consent, monitor patients), but no additional certification is legally required. Many psychiatrists pursue American Board of Obesity Medicine (ABOM) certification to formalize competency.

Do GLP-1 medications increase risk of depression or suicidal thoughts?

No. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. FDA and EMA reviews confirmed no causal link. Some trials even showed lower rates of depressive symptoms in GLP-1 groups, likely due to improved quality of life and reduced inflammation.

Can PMHNPs prescribe weight-loss medications independently?

It depends on your state:

• Full Practice Authority states (e.g., New York after 3,600 hours, Illinois after 4,000 hours + 250 CE hours): Yes, you can prescribe independently, including GLP-1s and controlled substances like phentermine (with some initial consulting requirements for Schedule II in some states).
• Reduced/Restricted Practice states (e.g., Texas, Florida, Pennsylvania): You must have a collaborative agreement or supervision with a physician. Your agreement must explicitly authorize weight-loss prescribing.

Can I prescribe phentermine (a controlled substance) via telehealth?

Federally, yes — through December 31, 2025 (under DEA waivers). But state laws override federal permissions. Florida prohibits prescribing controlled substances via telehealth except for psychiatric treatment (weight loss doesn’t qualify). Alabama requires an in-person exam. Most other states allow it during the federal waiver period. Always check your patient’s state law.

What are Florida’s specific rules for prescribing weight-loss medications?

Florida requires:

• Documented BMI ≥30 (or ≥27 with comorbidity)
• Comprehensive exam (history, physical, labs) before prescribing
• Written informed consent
• State-mandated ‘Weight-Loss Consumer Bill of Rights’ provided to patient
• Follow-ups every 3 months (face-to-face, which can be via telehealth)
• PDMP check before each controlled prescription
• Cannot prescribe controlled substances (phentermine) via telehealth for weight loss (not an approved exception under F.S. 456.47). GLP-1s (non-controlled) are allowed via telehealth.

Do insurers cover GLP-1 medications for weight loss?

Increasingly, yes:

• Private insurance: Many commercial plans cover GLP-1s (Wegovy, Saxenda, Mounjaro) with prior authorization. Typical requirements: BMI ≥30 or ≥27 with comorbidities, documentation of lifestyle interventions.
• Medicare: Will begin covering anti-obesity medications starting 2026 (major policy shift).
• Medicaid: Coverage varies by state; expanding.

Expect prior authorizations that require BMI documentation, comorbidities, and treatment plans.

How much does traditional patient acquisition cost vs. joining a platform like Klarity?

DIY marketing:

• SEO: $2,000-5,000/month for 6-12 months before results
• Google Ads: $200-400+ per booked patient (after failed clicks, no-shows, optimization)
• Directories: $35-100+ per booking + monthly subscription fees
• Total cost per new patient: $200-500+ when you factor in all costs, staff time, and no-shows.

Klarity model:

• Pay-per-appointment (standard listing fee per new patient booking)
• No upfront marketing spend, no monthly subscriptions
• Pre-qualified patients matched to your specialty and availability
• Built-in telehealth infrastructure, insurance credentialing, billing support
• You only pay when you see patients — guaranteed ROI vs. gambling on marketing

For providers starting out or scaling, Klarity removes patient acquisition risk entirely.

Is prescribing weight-loss medications within a PMHNP’s scope of practice?

Legally, scope is about competency, not just specialty title. If you’re treating a psychiatric patient’s antipsychotic-induced weight gain with a GLP-1, that’s arguably within psychiatric care. If you’re opening a standalone weight-loss clinic for the general public without additional training, state boards might scrutinize it.

Best practice:

• Pursue supplemental training (obesity management courses, certifications)
• Document that weight management is part of holistic psychiatric care
• If your state requires collaboration, ensure your supervising physician explicitly authorizes weight-loss prescribing in your agreement

What’s the reimbursement for weight-loss medication management visits?

• E/M codes (99202-99215 series): $75-$200 depending on complexity and payer
• Initial psychiatric evaluation with med management (90792): ~$200 (Medicare)
• Routine med checks (99213-99214): $75-$120 (Medicare)

Psychiatrists (MD/DO): Paid at 100% of physician fee schedulePMHNPs: Paid at 85% by Medicare, 85-100% by private insurers (Illinois Medicaid pays 100%)

Telehealth parity laws in California, New York, Illinois, Pennsylvania ensure equal reimbursement for telehealth visits.

What training should I get before prescribing weight-loss medications?

Consider:

• American Board of Obesity Medicine (ABOM) certification: ~60 hours obesity-focused CME + exam. Open to all physicians (including psychiatrists). Formalizes competency.
• CME courses in obesity pharmacotherapy, metabolic health, nutrition
• Mentorship with bariatric medicine or endocrinology colleagues
• Attend conferences (Obesity Medicine Association, American Psychiatric Association metabolic health sessions)

Training strengthens your scope-of-practice legitimacy and ensures you’re treating patients safely and effectively.

Next Steps: Should You Add Weight Management to Your Practice?

If you’re a psychiatrist or PMHNP looking to expand services, weight-loss medication management can be:

✅ Clinically meaningful: Address the metabolic side effects of psychiatric meds, improve patient outcomes✅ Financially viable: Growing insurance coverage, strong reimbursement, scalable via telehealth✅ Lower patient acquisition cost: Platforms like Klarity remove the $200-500+ CAC gamble of DIY marketing

But it requires:

• Additional training (ABOM certification or equivalent)
• Understanding state-specific regulations (especially Florida, Texas, California)
• Navigating telehealth restrictions (Florida’s phentermine ban, etc.)
• Documenting appropriate indications, consent, and follow-ups

The opportunity is real. Medicare’s 2026 coverage expansion will bring millions of new patients seeking GLP-1 therapy. Psychiatric providers who position themselves now — with proper training and compliant practice models — can build sustainable, meaningful weight management services.

Ready to join a platform that handles patient acquisition, credentialing, and infrastructure so you can focus on care?

Klarity Health connects psychiatrists and PMHNPs with pre-qualified patients seeking both mental health and weight management services. No upfront marketing spend. No gambling on Google Ads. Pay only when you see patients.

Explore Klarity’s provider network and see if it’s the right fit for your practice growth.

Citations and Sources

1. MedicalDirector Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (www.medicaldirectorco.com) | Industry Compliance Guide | Updated 2025

2. MedicalDirector Co. – ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (www.medicaldirectorco.com) | State-Specific Compliance Guide | Updated 2025

3. MedicalDirector Co. – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (www.medicaldirectorco.com) | State-Specific Compliance Guide | Updated 2025

4. Fla. Admin. Code R. 64B15-14.004 – Standards for Prescription of Obesity Drugs (www.law.cornell.edu) | Official State Regulation (Florida Administrative Code) | Effective Aug 8, 2022 (current through 2026)

5. Mondaq (Foley & Lardner) – ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (www.mondaq.com) | Legal Industry Analysis | July 24, 2023

6. RxAgent.co – ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ (rxagent.co) | Pharmacy Compliance Insight | Dec 16, 2025

7. The Nurse Practitioner Journal – ’36th Annual APRN Legislative Update’ (Susanne J. Phillips) (journals.lww.com) | Peer-Reviewed Professional Journal | Jan 2024 (covers 2023 updates)

8. DrLewis.com (E. Lewis, MD) – ‘Should Psychiatrists Prescribe GLP-1s? An Evidence-Based Perspective’ (drlewis.com) | Professional Analysis by Board-Certified Psychiatrist and Obesity Medicine Specialist | Jan 4, 2026

9. DrLewis.com – ‘GLP-1 Medications & Mental Health: Facts vs Myths’ (drlewis.com) | Professional Analysis | Nov 26, 2025

10. Axios – ‘COVID-era telehealth prescribing extended again’ (www.axios.com) | News Outlet (Health Policy) | Nov 18, 2024

11. Axios – ‘Trump announces Medicare coverage of weight-loss drugs’ (www.axios.com) | News Outlet | Nov 6, 2025

12. TheraThink – ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ (therathink.com) | Industry Billing Resource | Updated 2026

13. Blue Cross Blue Shield TX – Provider Notice on GLP-1 Supply Limit (www.bcbstx.com) | Insurer Communication | Oct 4, 2024

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting